Key Insights

Highlights

Success Rate

96% trial completion (above average)

Published Results

462 trials with published results (34%)

Research Maturity

1113 completed trials (81% of total)

Clinical Risk Assessment

Based on trial outcomes

Low Risk

Score: 17/100

Termination Rate

3.1%

42 terminated out of 1376 trials

Success Rate

96.4%

+9.8% vs benchmark

Late-Stage Pipeline

36%

495 trials in Phase 3/4

Results Transparency

42%

462 of 1113 completed with results

Key Signals

462 with results96% success42 terminated

Data Visualizations

Phase Distribution

1,204Total
Not Applicable (174)
P 1 (260)
P 2 (275)
P 3 (265)
P 4 (230)

Trial Status

Completed1,113
Unknown80
Recruiting53
Terminated42
Withdrawn34
Active Not Recruiting30

Trial Success Rate

96.4%

Benchmark: 86.5%

Based on 1113 completed trials

Clinical Trials (1376)

Showing 20 of 20 trials
NCT07149428Enrolling By Invitation

Longitudinal Deep Phenotyping of Central Mechanisms in Dysosmia: A Pilot Study Using Electrobulbogram (EBG), Functional MRI (fMRI), and Diffusion-Weighted Imaging (DWI)

NCT07703514Phase 1Not Yet RecruitingPrimary

Safety and Immunogenicity of Chimeric Hemagglutinin mRNA Vaccine Candidates

NCT07739446Not ApplicableEnrolling By Invitation

Randomized Controlled Trial to Evaluate the Efficacy of Surgical Masks in Preventing Acute Respiratory Infections

NCT07215858Phase 2RecruitingPrimary

BPL-1357 Against H1N1 Influenza Virus Challenge

NCT01386424Recruiting

Screening for LID Clinical Studies Unit Healthy Volunteer Protocols

NCT07737106Phase 1CompletedPrimary

Phase I/II Clinical Trial of Influenza Vaccine (Split Virion), Inactivated (High Dose)

NCT04794829CompletedPrimary

Natural History of Systemic and Nasal Mucosal Immunity to Influenza and SARS-CoV-2 in Adults After Vaccination

NCT07485855Phase 3Recruiting

Influenza Vaccination Strategy for Patients With Hematologic Malignancy

NCT06518577Phase 4CompletedPrimary

Immunogenicity of Influenza Vaccinations

NCT07110532Phase 1RecruitingPrimary

pH1N1 Blinded Challenge Study

NCT06560151Phase 2CompletedPrimary

Assess Safety and Immunogenicity of A/H5 Inactivated Monovalent Influenza Vaccines at Different Antigen Dose Levels Adjuvanted With AS03 or MF59

NCT04712539Phase 2Recruiting

Baloxavir and Oseltamivir for the Treatment of Severe Influenza Infection in Immunocompromised Patients

NCT07229547Phase 3RecruitingPrimary

A Multicenter, Randomized, Double-blind, Placebo-controlled Phase III Clinical Study to Evaluate the Safety and Efficacy of Onradivir Tablets in Participants Aged 12 to 17 Years With Uncomplicated Influenza A.

NCT05765396Completed

SARS-CoV-2/COVID-19 Study of Next Generation Non-Invasive Passive Detection Technologies (Level42)

NCT05968989Phase 1CompletedPrimary

Trial to Evaluate the Safety, Tolerability, and Immunogenicity of a Mosaic Hexavalent Influenza Vaccine VRC-FLUMOS0116-00-VP (FluMos-v2) in Healthy Adults

NCT06692400Not ApplicableRecruiting

The Effects of Endotracheal Suctioning on Pain and Serum Markers

NCT01191853Completed

Cellular and Molecular Characterization of the Immune Response in Healthy NIH Employees atBaseline, and After Immunization With the H1N1 or Seasonal Influenza Vaccines

NCT07508189Not ApplicableActive Not RecruitingPrimary

Communication Intervention to Improve Influenza Vaccination Rates Among Elderly in Can Tho

NCT07678619Not ApplicableEnrolling By Invitation

Smart Analysis and Decision-Making for Emerging Infectious Diseases

NCT07651761Not ApplicableEnrolling By InvitationPrimary

Patient-Centered Practical Vaccine Talk For Busy Clinicians

Scroll to load more

Research Network

Activity Timeline